WuXi Biologics (Cayman) Inc.
2269
Rangering i aksjer
#987
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman)... Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Aksjekurs
$5.77
Markedsverdi
$23.74B
Endring (1 dag)
-8.38%
Endring (1 år)
25.13%
Land
CN
Handel WuXi Biologics (Cayman) Inc. (2269)
Kategori
Healthcare
P/S-forhold for WuXi Biologics (Cayman) Inc. (2269)
P/S-forhold per October 2026 TTM: 6.71
Ifølge WuXi Biologics (Cayman) Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 6.71. Ved slutten av 2024 hadde selskapet et P/S-forhold på 3.60.
P/S-historikk for WuXi Biologics (Cayman) Inc. fra 2014 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 6.71 | 23.99% |
| 2025 | 5.41 | 50.12% |
| 2024 | 3.60 | -43.29% |
| 2023 | 6.36 | -55.99% |
| 2022 | 14.44 | -55.19% |
| 2021 | 32.23 | -49.91% |
| 2020 | 64.36 | 118.36% |
| 2019 | 29.47 | 29.19% |
| 2018 | 22.81 | -6.32% |
| 2017 | 24.35 | -16.00% |
| 2016 | 28.99 | -39.77% |
| 2015 | 48.14 | -37.59% |
| 2014 | 77.13 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | 49.41% |
US
|
|
| 40.55 | 504.51% |
US
|
|
| 3.96 | -40.95% |
AU
|
|
| 10.15 | 51.26% |
NL
|
|
| - | - |
CH
|
